With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.

Just look at Eli Lilly (NYSE:LLY).

The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 74,800 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Helping, demand could rocket even higher with millions of people in need of help.

According to the World Health Organization, obesity has more than doubled since 1990. Global adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. Over 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity.

In short, with millions of people in need of help, obesity drug treatment demand should rocket. And it’s why some of the smartest biotech stocks to buy are those with weight loss drugs.

Viking Therapeutics (VKTX)

Source: Shutterstock

About a year ago, I first mentioned Viking Therapeutics (NASDAQ:VKTX) as it traded at $22 a share. After watching it rally to nearly $100, it pulled back to $48, where it’s again a buying opportunity.

For one, the company reported that the injectable form of its treatment helped patients lose up to 13.1% of their weight after 13 weeks in Phase 2 trials. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials.

Two, thanks to Viking’s success in obesity drug trials, analysts at BTIG just reiterated a buy rating with a price target of $125 a share.

Three, as pointed out by Motley Fool contributor George Budwell, Viking’s treatment has been “pegged as a potential $21 billion a year therapy by some analysts – that is, if it can gain timely approvals in both the U.S. and the European Union.”

Altimmune (ALT)

Source: metamorworks / Shutterstock

Citing data from its MOMENTUM trial, Altimmune’s (NASDAQ:ALT) pemvidutide treatment led to weight loss while preserving lean mass, as noted by Seeking Alpha.

Phase 2 results showed that patients lost an average of 15.6% of their body weight at 48 weeks at the highest dose. The study also found that the treatment led to better lean mass preservation as compared to other similar weight loss treatments.

“Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function,” CEO Vipin Garg said in a news release. “We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.”